DEF: Fonar Corp. Schedules Annual Shareholder Meeting

Fonar Corporation has announced its Annual Meeting of Stockholders for June 17, 2026, to elect directors, approve executive compensation, and ratify auditor selection.

Summary

• Fonar Corporation will hold its Annual Meeting of Stockholders on Wednesday, June 17, 2026, at the Hilton Long Island Huntington Hotel in Melville, New York.
• The meeting's agenda includes the election of five directors, an advisory vote on executive compensation, and the ratification of CohnReznick LLP as the independent auditors for the fiscal year ending June 30, 2026.
• Stockholders of record as of April 20, 2026, are entitled to vote.
• The company is also separately soliciting stockholder approval for a going-private transaction, with a special meeting scheduled for May 28, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reported decline in net and operating income, increased expenses, and an adverse opinion on internal controls, despite the company's long-term profitability history and unique product offerings.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing operational stability.
• The board composition includes several independent directors, aligning with good corporate governance practices.
• The company has a history of positive net income and income from operations for 63 consecutive quarters as of June 30, 2025.

Negatives

• The company's financial statements for the fiscal year ended June 30, 2025, received an adverse opinion from auditors regarding internal control over financial reporting due to a material weakness in logical access controls within IT systems.
• The company faces significant risks related to reduced reimbursement rates, inflation impacting costs, cybersecurity threats, and potential changes in Florida insurance law.

Risks

• Reduced reimbursement rates from Medicare, government programs, and private insurance companies are impacting profitability.
• Inflation has increased costs for materials and labor, making organic growth and new center profitability more challenging.
• Cybersecurity threats pose a risk of operational disruption and significant response costs; a material weakness in IT controls was identified.
• Changes in Florida insurance law, particularly potential repeal of no-fault insurance, could lead to payment delays and negatively impact operations.
• Competition in the diagnostic imaging services market is high, especially in Florida, potentially deterring future expansion.
• Pressure to control healthcare costs from managed care organizations could negatively impact utilization and pricing.
• Changes in eligibility for government programs or increased patient financial responsibility could lead to reduced reimbursement or uncollectible receivables.
• Compliance with federal and state privacy and information security laws (like HIPAA) is critical and non-compliance could have material adverse effects.
• Lower reimbursement rates for MRI scanners are reducing demand and sales volumes, impacting economies of scale and profit margins.
• Manufacturing competition from larger companies with greater financial resources exists, although Fonar is unique in its Upright MRI technology.
• Adverse changes in domestic and global economic conditions, including recessions or credit market disruptions, could negatively affect operations.

Future Outlook

The company expects to continue its growth strategy by upgrading and expanding existing facilities and acquiring new sites. Investments are being made in technology to improve scan times and operational efficiency. The company anticipates continued profitability and believes its current cash balance and capital resources are adequate to support operations through September 30, 2026.

Management Comments

• Timothy R. Damadian, Chairman and CEO, expressed pride in the company's long-term success, noting 63 consecutive quarters of positive net income and income from operations.
• He highlighted the foundational role of his father, Dr. Raymond V. Damadian, in the development of MRI technology.
• Management is committed to maintaining innovation through R&D investments and improving the operation of its physician and diagnostic services management segment.

Industry Context

StockSavvy.ai notes that Fonar operates in the highly competitive diagnostic imaging market, facing pressures from healthcare cost containment and evolving insurance regulations. The company's focus on its unique Upright MRI technology and AI-powered software upgrades positions it to address specific market needs, but it must navigate significant industry-wide risks.

Comparison to Industry Standards

• Fonar's Upright MRI scanner operates at a 0.6 Tesla field strength, which is considered mid-field. Competitors primarily focus on high-field (1.0 T and above) MRI scanners.
• The company's diagnostic management segment (HMCA) faces competition from large health systems and other independent imaging centers.
• While many competitors have greater financial resources, Fonar differentiates itself with its unique Upright MRI technology and its ability to scan patients in weight-bearing positions.

Management Changes

Corporate Governance

Legal Proceedings

• The company states that it is not involved in any material legal proceedings threatened or pending.
• However, it notes that cybersecurity threats could lead to future litigation.

Related Party Transactions

• Timothy Damadian, CEO, owns three Florida imaging facilities that pay HMCA (a Fonar subsidiary) approximately $11.9 million annually in management fees.
• Magnetic Resonance Management, LLC, owned by Timothy Damadian, purchased MRI equipment for $576,857, payable via a 9% promissory note maturing in December 2028.
• Bensonhurst MRI Limited Partnership, in which Timothy Damadian has an interest, has service and maintenance agreements with Fonar for its MRI scanners, totaling $180,000 annually, plus reimbursable salaries and marketing expenses.
• Integrity Healthcare Management, LLC, owned by Timothy Damadian, holds a 7.1% interest in HMCA's Class A membership.
• Radian Healthcare Management, LLC, owned by Timothy Damadian's son-in-law, provided personnel recruitment services for fees of $165,000 in FY2025 and $200,000 in FY2024.
• Directors Ronald Lehman, Jessica Maher, and former director Claudette J.V. Chan hold minor interests in HMCA's Class A membership.

Stakeholder Impact

• Shareholders: The company's financial performance, governance, and potential going-private transaction will directly impact shareholder value.
• Employees: The company's financial health and operational efficiency affect job security and compensation. Cybersecurity risks also pose a threat.
• Customers (MRI centers): HMCA's services are crucial for their operations; changes in reimbursement and competition can affect their business.
• Suppliers: The company's purchasing power and financial stability influence its relationships with suppliers of parts and services.
• Creditors: The company's liquidity and debt levels are important for creditors.

Next Steps

• Elect five Directors to the Board of Directors.
• Approve, on an advisory basis, the compensation of the Company's named executive officers.
• Ratify the selection of CohnReznick LLP as the Company's independent auditors for the fiscal year ending June 30, 2026.
• Consider a going-private transaction at a special meeting on May 28, 2026.

Key Dates

Recommendation

Fonar Corporation presents a mixed picture. While the company has a long history of profitability and a unique product in the Upright MRI, the recent decline in financial performance, increased expenses due to credit loss reserves, and a material weakness in internal controls are significant concerns. The potential going-private transaction adds further uncertainty. Given these factors, a 'hold' recommendation is appropriate, pending clarity on the going-private transaction and remediation of internal control weaknesses.

Keywords

Fonar Corporation, Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Auditor Ratification, MRI, Diagnostic Imaging, Healthcare, SEC Filing, DEF 14A